Table 4.
Effects of selected compounds on SARS-CoV2 and HCoV-OC43 yield reduction and cell viability.
| Compound | Virus titer reduction Log10 (mean ± SDa) at highest tested dose (μM) | EC50b (μM) (mean ± SD) |
CC50c (μM) (mean ± SD) |
|---|---|---|---|
| SARS-CoV2 | |||
| Grazoprevir | 3.9 ± 0.07 (100 μM) | 3.3 ± 0.9 | 118 ± 6 |
| Lurasidone | 1.3 ± 0.3 (100 μM) | 6.4 ± 3.9 | >1000 |
| Elbasvir | 0.6 ± 0.2 (100 μM) | 14.4 ± 7.9 | >1000 |
| HCoV-OC43 | |||
| Alectinib | 2.9 ± 0.1 (33 μM) | 1.0 ± 0.1 | >1000 |
| Lurasidone | 6.3 ± 1.5 (100 μM) | 8.3 ± 2.0 | >1000 |
| Elbasvir | 1.4 ± 0.2 (100 μM) | 1.3 ± 0.4 | >1000 |
Virus titer reduction is the difference between log10 values of PFU (SARS-CoV2) or FFU/mL (HCoV-OC43) from infected untreated controls and infected-treated at the highest tested dose. Mean virus titer for untreated control was 9.8 × 103 pfu/mL and 3 × 106 FFU/mL for SARS-CoV2 and HCoV-OC43, respectively.
a
Standard deviation.
b
Half maximal effective concentration obtained by virus yield reduction assay.
c
Half maximal cytotoxic concentration obtained by Alamar Blue (SARS-CoV2) and MTS (HCoV-OC43) assays.